MA38390B1 - Composés tétrahydropyrrolothiazines - Google Patents

Composés tétrahydropyrrolothiazines

Info

Publication number
MA38390B1
MA38390B1 MA38390A MA38390A MA38390B1 MA 38390 B1 MA38390 B1 MA 38390B1 MA 38390 A MA38390 A MA 38390A MA 38390 A MA38390 A MA 38390A MA 38390 B1 MA38390 B1 MA 38390B1
Authority
MA
Morocco
Prior art keywords
tetrahydropyrrolothiazine
compounds
tetrahydropyrrolothiazine compounds
compound
formula
Prior art date
Application number
MA38390A
Other languages
English (en)
Other versions
MA38390A1 (fr
Inventor
Steven James Green
Dustin James Mergott
Brian Morgan Watson
Jr Leonard Larry Winneroski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38390A1 publication Critical patent/MA38390A1/fr
Publication of MA38390B1 publication Critical patent/MA38390B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé de formule (i), dans laquelle r est h ou f ; et a est : (a), (b), (c) ou (d) ; ou un sel pharmaceutiquement acceptable de celui-ci.
MA38390A 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines MA38390B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361776819P 2013-03-12 2013-03-12
PCT/US2014/020070 WO2014143579A1 (fr) 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines

Publications (2)

Publication Number Publication Date
MA38390A1 MA38390A1 (fr) 2018-08-31
MA38390B1 true MA38390B1 (fr) 2020-01-31

Family

ID=50382615

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38390A MA38390B1 (fr) 2013-03-12 2014-03-04 Composés tétrahydropyrrolothiazines

Country Status (38)

Country Link
US (3) US8841293B1 (fr)
EP (1) EP2970336B1 (fr)
JP (1) JP6095844B2 (fr)
KR (1) KR101688761B1 (fr)
CN (1) CN105026404B (fr)
AP (1) AP2015008713A0 (fr)
AR (1) AR094918A1 (fr)
BR (1) BR112015018738A8 (fr)
CA (1) CA2898500C (fr)
CL (1) CL2015002529A1 (fr)
CR (1) CR20150418A (fr)
CY (1) CY1119585T1 (fr)
DK (1) DK2970336T3 (fr)
EA (1) EA026006B1 (fr)
ES (1) ES2653421T3 (fr)
HK (1) HK1212694A1 (fr)
HR (1) HRP20171851T1 (fr)
HU (1) HUE037487T2 (fr)
IL (1) IL240903B (fr)
JO (1) JO3317B1 (fr)
LT (1) LT2970336T (fr)
MA (1) MA38390B1 (fr)
ME (1) ME02910B (fr)
MX (1) MX2015012628A (fr)
MY (1) MY180083A (fr)
NO (1) NO3039297T3 (fr)
NZ (1) NZ712207A (fr)
PE (1) PE20151542A1 (fr)
PH (1) PH12015502031B1 (fr)
PL (1) PL2970336T3 (fr)
PT (1) PT2970336T (fr)
RS (1) RS56645B1 (fr)
SG (1) SG11201507499XA (fr)
SI (1) SI2970336T1 (fr)
TN (1) TN2015000340A1 (fr)
TW (1) TWI593692B (fr)
UA (1) UA112941C2 (fr)
WO (1) WO2014143579A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013276617B9 (en) 2012-06-13 2018-03-29 F. Hoffmann-La Roche Ag New diazaspirocycloalkane and azaspirocycloalkane
SI2900669T1 (sl) 2012-09-25 2019-12-31 F. Hoffmann-La Roche Ag Derivati heksahidropirolo(3,4-C)pirola in sorodne spojine kot zaviralci avtotaksina (ATX) in kot zaviralci tvorbe lizofosfatidne kisline (LPA) za zdravljenje npr. bolezni ledvic
EP2912041B1 (fr) 2012-10-26 2016-12-14 Eli Lilly and Company Derivés de tetrahydropyrrolothiazine en tant qu'inhibiteurs de bace
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MY187449A (en) 2013-11-26 2021-09-22 Hoffmann La Roche New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
TWI684452B (zh) 2014-03-14 2020-02-11 美國禮來大藥廠 胺基噻嗪化合物
PE20161223A1 (es) 2014-03-26 2016-11-12 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa)
DK3122750T3 (da) 2014-03-26 2019-11-04 Hoffmann La Roche Bicykliske forbindelser som autotaxin (ATX)- og lysofosfatidsyre (LPA)-produktionshæmmere
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
JP6886967B2 (ja) 2015-09-04 2021-06-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ フェノキシメチル誘導体
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
BR112018006024A2 (pt) 2015-09-24 2020-05-12 F. Hoffmann-La Roche Ag Compostos bicíclicos como inibidores de atx
MA42923A (fr) 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
CN107614505B (zh) 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 作为双重atx/ca抑制剂的新型二环化合物
AR107774A1 (es) * 2016-03-16 2018-05-30 Lilly Co Eli Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JP7177773B2 (ja) 2016-12-15 2022-11-24 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのオキサジン誘導体および使用方法
MX2019007104A (es) 2016-12-15 2019-11-05 Amgen Inc Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso.
MX2019007100A (es) * 2016-12-15 2019-12-16 Amgen Inc Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
MX2019007102A (es) 2016-12-15 2019-12-16 Amgen Inc Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
AU2017378316B2 (en) 2016-12-15 2021-04-01 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
WO2018167113A1 (fr) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag Nouveaux composés bicycliques utilisés en tant qu'inhibiteurs d'atx

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
AU2003219955A1 (en) * 2002-03-22 2003-10-13 Eli Lilly And Company Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
KR20080029965A (ko) 2005-06-14 2008-04-03 쉐링 코포레이션 아스파르틸 프로테아제 억제제
EP2597087B1 (fr) 2005-10-25 2016-03-30 Shionogi&Co., Ltd. Dérivés dihydrooxazine et tétrahydropyrimidine comme inhibiteurs de BACE 1
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
AU2009205072C1 (en) * 2008-01-18 2016-10-13 Eisai R & D Management Co., Ltd. Condensed aminodihydrothiazine derivative
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
CA2727859C (fr) 2008-06-13 2016-11-01 Shionogi & Co., Ltd. DERIVE HETEROCYCLIQUE CONTENANT DU SOUFRE AYANT UNE ACTIVITE INHIBANT LA ß-SECRETASE
US8198269B2 (en) 2008-09-30 2012-06-12 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
US20120245155A1 (en) 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2694521B1 (fr) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Composés de dioxyde de thiadiazine fusionnée à la pyrrolidine en tant qu'inhibiteurs de bace, compositions et leur utilisation
WO2012162334A1 (fr) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Composés destinés à la réduction de la production de bêta-amyloïdes
JO3143B1 (ar) * 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين

Also Published As

Publication number Publication date
EA201591491A1 (ru) 2016-01-29
BR112015018738A8 (pt) 2018-01-23
US8841293B1 (en) 2014-09-23
AR094918A1 (es) 2015-09-09
LT2970336T (lt) 2018-01-10
US20150157641A1 (en) 2015-06-11
PT2970336T (pt) 2017-12-21
WO2014143579A1 (fr) 2014-09-18
AP2015008713A0 (en) 2015-09-30
CN105026404B (zh) 2016-11-23
TWI593692B (zh) 2017-08-01
NZ712207A (en) 2019-09-27
HUE037487T2 (hu) 2018-08-28
PE20151542A1 (es) 2015-10-28
PH12015502031A1 (en) 2016-01-18
DK2970336T3 (da) 2017-11-13
MY180083A (en) 2020-11-20
KR20150119070A (ko) 2015-10-23
PH12015502031B1 (en) 2016-01-18
IL240903A0 (en) 2015-10-29
KR101688761B1 (ko) 2016-12-21
CL2015002529A1 (es) 2016-03-28
ME02910B (fr) 2018-04-20
TN2015000340A1 (en) 2017-01-03
CN105026404A (zh) 2015-11-04
CA2898500A1 (fr) 2014-09-18
UA112941C2 (uk) 2016-11-10
CY1119585T1 (el) 2018-03-07
RS56645B1 (sr) 2018-03-30
US8987254B2 (en) 2015-03-24
IL240903B (en) 2018-12-31
MA38390A1 (fr) 2018-08-31
SI2970336T1 (sl) 2017-11-30
PL2970336T3 (pl) 2018-03-30
JP6095844B2 (ja) 2017-03-15
ES2653421T3 (es) 2018-02-07
HRP20171851T1 (hr) 2018-01-12
US20140275044A1 (en) 2014-09-18
EP2970336B1 (fr) 2017-10-04
AU2014228351A1 (en) 2015-09-17
EP2970336A1 (fr) 2016-01-20
MX2015012628A (es) 2016-07-07
JO3317B1 (ar) 2019-03-13
TW201520217A (zh) 2015-06-01
SG11201507499XA (en) 2015-10-29
EA026006B1 (ru) 2017-02-28
BR112015018738A2 (pt) 2017-07-18
HK1212694A1 (zh) 2016-06-17
NO3039297T3 (fr) 2018-03-10
CA2898500C (fr) 2017-11-14
JP2016512252A (ja) 2016-04-25
US20140350245A1 (en) 2014-11-27
CR20150418A (es) 2015-09-16

Similar Documents

Publication Publication Date Title
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA52948B1 (fr) Composés
MA38472A1 (fr) Composé peptidique
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
BR112017006253A2 (pt) novos compostos
MA46337B1 (fr) Composé de pyridine
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
EA201690172A1 (ru) Полиморф ингибиторов syk
EA201792021A1 (ru) Ингибитор jak
EA201690911A1 (ru) Соединения диметилбензойной кислоты
MA40302A1 (fr) Dérivés de carbazole
MA38583B1 (fr) Dérivés de dolastatine 10 et d'auristatines
MA38645B1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
MA37686A1 (fr) Composés phénoxyéthyl pipéridine
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
MA39305A3 (fr) Dérivés d'éthynyle
EA201690924A1 (ru) Фторфенилпиразольные соединения
MA38857A1 (fr) Dérivés de 1-(pipérazin-1-yl)-2-([1,2,4]triazol-1-yl)-éthanone
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
EA201690593A1 (ru) Новые соединения мочевины
EA201400269A1 (ru) Способ синтеза соединений 7,8-диметокси -1,3-дигидро-2h-3-бензазепин-2-она и применение в синтезе ивабрадина
MA42602B1 (fr) Antagonistes du recepteur cgrp